Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
14 07 2022
Historique:
received: 11 11 2021
pubmed: 22 4 2022
medline: 19 7 2022
entrez: 21 4 2022
Statut: ppublish

Résumé

Low cognitive scores are risk factors for cardiovascular outcomes. Whether this relationship is stronger using novel cognitive indices is unknown. Participants in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial who completed both the Montreal Cognitive Assessment (MoCA) score and Digit Substitution Test (DSST) at baseline (N = 8772) were included. These scores were used to identify participants with baseline substantive cognitive impairment (SCI), defined as a baseline score on either the MoCA or DSST ≥ 1.5 SD below either score's country-specific mean, or SCI-GM, which was based on a composite index of both scores calculated as their geometric mean (GM), and defined as a score that was ≥ 1.5 SD below their country's average GM. Relationships between these measures and incident major adverse cardiovascular events (MACE), and either stroke or death were analyzed. Compared with 7867 (89.7%) unaffected participants, the 905 (10.3%) participants with baseline SCI had a higher incidence of MACE (unadjusted hazard ratio [HR] 1.34; 95% CI 1.11, 1.62; P = 0.003), and stroke or death (unadjusted HR 1.60; 95% CI 1.33, 1.91; P < 0.001). Stronger relationships were noted for SCI-GM and MACE (unadjusted HR 1.61; 95% CI 1.28, 2.01; P < 0.001), and stroke or death (unadjusted HR 1.85; 95% CI 1.50, 2.30; P < 0.001). For SCI-GM but not SCI, all these relationships remained significant in models that adjusted for up to 10 SCI risk factors. Country-standardized SCI-GM was a strong independent predictor of cardiovascular events in people with type 2 diabetes in the REWIND trial.

Identifiants

pubmed: 35446415
pii: 6569991
doi: 10.1210/clinem/dgac200
doi:

Substances chimiques

Hypoglycemic Agents 0
Incretins 0

Banques de données

ClinicalTrials.gov
['NCT01394952']

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e3448-e3454

Subventions

Organisme : Eli Lilly and Company

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Tali Cukierman-Yaffe (T)

Endocrinology Institute, Sheba Medical Center, Ramat-Gan, and Epidemiology Department, Sackler School of Medicine, Herceg Institute of Aging, Tel Aviv University, Tel Aviv, Israel.

Hertzel C Gerstein (HC)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.

Jan Basile (J)

Medical University of South Carolina, Ralph H. Johnson VA Medical Center, Charleston, SC, USA.

M Angelyn Bethel (MA)

Eli Lilly and Company, Indianapolis, IN, USA.

Ernesto G Cardona-Muñoz (EG)

CUCS-Universidad de Guadalajara, Mexico.

Ignacio Conget (I)

Endocrinology and Nutrition Dpt. Hospital Clinic i Universitari, Barcelona, Spain.

Gilles Dagenais (G)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Edward Franek (E)

Mossakowski Medical Research Centre, Polish Academy of Sciences and Central Clinical Hospital MSWiA, Warsaw, Poland.

Stephanie Hall (S)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.

Nicolae Hancu (N)

Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.

Petr Jansky (P)

University Hospital Motol, Prague.

Mark Lakshmanan (M)

Eli Lilly and Company, Indianapolis, IN, USA.

Fernando Lanas (F)

Universidad de La Frontera, Temuco, Chile.

Lawrence A Leiter (LA)

Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Canada.

Patricio Lopez-Jaramillo (P)

Masira Research Institute, Medical School, Universidad de Santander UDES, Bucaramanga, Colombia.

Valdis Pirags (V)

University of Latvia, Pauls Stradiņš Clinical University Hospital, Riga, Latvia.

Nana Pogosova (N)

National Medical Research Center of Cardiology, Moscow, Russia.

Jeffrey Probstfield (J)

Department of Medicine, University of Washington, Seattle, WA,USA.

Purnima Rao-Melacini (P)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.

Chinthanie Ramasundarahettige (C)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.

Peter J Raubenheimer (PJ)

Department of Medicine, University of Cape Town, Cape Town, South Africa.

Matthew C Riddle (MC)

Department of Medicine, Oregon Health & Science University Portland, OR, USA.

Lars Rydén (L)

Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden.

Jonathan E Shaw (JE)

Baker Heart and Diabetes Institute, Melbourne, Australia.

Wayne H-H Sheu (WH)

Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.

Theodora Temelkova-Kurktschiev (T)

Robert Koch Medical Center, Sofia, Bulgaria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH